Kidney cancer surgery combined with immunotherapy treatment
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies whether removing the primary kidney tumor (cytoreductive nephrectomy) in addition to standard immunotherapy treatment can help people with metastatic kidney cancer. It is for patients whose cancer has not gotten worse after 6 months of initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a type of kidney cancer called clear cell, papillary, or chromophobe renal cell carcinoma, which may include sarcomatoid features.
- You are in good enough health to be considered for surgery (your cancer doctor and anesthesiologist will decide).
- You have started treatment with a combination of immunotherapy drugs (such as two immunotherapies, or one immunotherapy plus a targeted therapy pill).
- Your cancer has not progressed (grown or spread) after about 6 months of starting your first treatment.
- You still have the original tumor in your kidney (it has not been removed yet).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
This trial studies whether removing the kidney tumor (cytoreductive nephrectomy) before treatment can improve outcomes for people with metastatic clear-cell kidney cancer. All participants are expected to receive standard immunotherapy (nivolumab plus ipilimumab), and the study focuses on the role of surgery in the “immuno-oncology era.”
This study tests whether adding surgery to remove the kidney improves outcomes compared with continuing immunotherapy without surgery. It is for people with metastatic kidney cancer whose disease has not worsened after initial immunotherapy.
This trial studies whether removing the kidney tumor with “deferred cytoreductive nephrectomy” (surgery at a later time) works best for people whose metastatic kidney cancer is already present. It compares a standard treatment approach using either immunotherapy (nivolumab/ipilimumab) or a targeted pill plus immunotherapy (TKI/IO), with planned surgery afterward.
This trial tests whether giving immunotherapy before surgery can help people with advanced kidney cancer. The goal is to see if waiting on surgery and starting with medication that boosts the immune system is safe and effective.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.